Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial

Abstract

Key Points Noninferiority of anagrelide in comparison with hydroxyurea in WHO-essential thrombocythemia, a phase 3 trial

Keywords

AnagrelideMedicineDiscontinuationEssential thrombocythemiaHydroxycarbamideTolerabilityInternal medicineRandomized controlled trialAdverse effectGastroenterologySurgeryClinical endpointVenous thrombosisThrombosisPolycythemia veraChemotherapy

Affiliated Institutions

Related Publications

Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study

Tiziano Barbui , Jüergen Thiele , Francesco Passamonti +19 more

Purpose The WHO diagnostic criteria underscore the role of bone marrow (BM) morphology in distinguishing essential thrombocythemia (ET) from early/prefibrotic primary myelofibro...

2011 Journal of Clinical Oncology 524 citations

Masked polycythemia Vera (mPV): Results of an international study

Tiziano Barbui , Jürgen Thiele , Heinz Gisslinger +13 more

We examined the baseline features and clinical outcomes of 140 patients presenting with JAK2V617F positivity and a bone marrow morphology conforming with WHO criteria of polycyt...

2013 American Journal of Hematology 141 citations

Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis

Tiziano Barbui , J. Thiele , Alessandro M. Vannucchi +1 more

2015 Blood Cancer Journal 119 citations

Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification

Jürgen Thiele , Hans Michael Kvasnicka , Leonhard Müllauer +3 more

Abstract Controversy persists regarding the role of histopathology in the distinction between essential thrombocythemia (ET) and early-prefibrotic primary myelofi-brosis (PMF) p...

2011 Blood 171 citations

An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms

Ayalew Tefferi , J. Thiele , Alessandro M. Vannucchi +1 more

2014 Leukemia 215 citations

Publication Info

Year: 2013
Type: article
Volume: 121
Issue: 10
Pages: 1720-1728
Citations: 318
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

318

OpenAlex

Cite This

APA Style

                            
                                
                                    Heinz Gisslinger, 
                                
                                    Mirjana Gotić, 
                                
                                    Jerzy Hołowiecki
                                
                                et al.
                            
                            (2013). 
                            Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. 
                            Blood
                            , 121
                            (10)
                            , 1720-1728.
                            https://doi.org/10.1182/blood-2012-07-443770
                        

Identifiers

DOI: 10.1182/blood-2012-07-443770